Ind Swift Laboratories has made a strategic move into the sports and entertainment sector by approving the incorporation of a 50:50 joint venture to participate in the inaugural Chandigarh Premier League (CPL). The company's investment committee gave the green light for this venture during a meeting held on September 12, 2025.

Joint Venture Details

The joint venture will be structured as a Limited Liability Partnership (LLP) between Ind Swift Laboratories and Mr. Nikhil Goel. Key points of the venture include:

• Equal partnership: 50% contribution from each party
• Company's investment: Up to Rs. 2.00 crores
• Primary activities: Sponsorship/ownership of a cricket team in the CPL and participation in cricket tournaments and other sports-related initiatives

Strategic Rationale

Ind Swift Laboratories cited two main reasons for this investment:

1. The significant fan following and commercial potential of cricket in India
2. The strategic opportunity to associate with the CPL at its inception, enabling the company to build a strong presence in the sports and entertainment ecosystem

Regulatory Compliance

The company has emphasized that the investment does not constitute a related party transaction. The incorporation of the joint venture is subject to the completion of statutory and regulatory formalities.

Market Impact

This move represents a diversification for Ind Swift Laboratories, traditionally known for its pharmaceutical operations. By entering the sports entertainment sector, the company is positioning itself to tap into the cricket market in India.

Future Prospects

While the immediate focus is on the Chandigarh Premier League, the joint venture's scope includes participation in other cricket tournaments and sports-related initiatives. This suggests a long-term commitment to building a presence in the sports sector.

The success of this venture could open new revenue streams for Ind Swift Laboratories and potentially enhance its brand visibility beyond the pharmaceutical industry.

Ind Swift Laboratories , a prominent pharmaceutical company, has reported a significant change in its shareholding pattern following a recent amalgamation scheme. The company's promoter and promoter group members have acquired a substantial number of equity shares, strengthening their position in the organization.

Key Highlights of the Acquisition

• Total shares acquired: 39,46,094 equity shares
• Acquisition method: Scheme of arrangement for amalgamation
• Approval authority: National Company Law Tribunal, Chandigarh Bench

Breakdown of Acquisitions

The acquisition involved six entities from the promoter and promoter group:

Impact on Shareholding

The acquisition has led to a notable increase in the promoter group's stake in Ind-Swift Laboratories Limited. Here's how the shareholding of key members changed:

• Essix Biosciences Limited: Increased from 34.33% to 34.04% of the total share capital
• S.R. Mehta: Increased from 0.32% to 0.66%
• Gopal Munjal: Increased from 0.08% to 0.43%
• V.R. Mehta: Increased from 0.07% to 0.42%
• Sunita Jain: Increased from 0.06% to 0.39%
• Neera Mehta: Increased from 0.34% to 0.59%

Regulatory Compliance

In compliance with regulatory requirements, Ind-Swift Laboratories Limited has made the necessary disclosures under:

1. Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015
2. Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Changes in Share Capital

Following the amalgamation and share allotment:

• The equity share capital of Ind-Swift Laboratories Limited increased from INR 73.49 crore to INR 81.61 crore.
• The total number of equity shares rose from 7,34,86,860 to 8,16,11,558.

Conclusion

This strategic move through the amalgamation scheme has significantly bolstered the promoter group's stake in Ind-Swift Laboratories Limited. The acquisition, valued at over INR 10 lakh, reflects the promoters' confidence in the company's future prospects and their commitment to its growth.